It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Create a wealth building plan for beginners that sets the foundation for financial success. Start your journey towards wealth today!
20,287 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As Nasdaq income options proliferate, investors weigh tax treatment and true take-home yields. A clear, current compa...
Prices may look flat, but the real bill for home buying in 2026 is higher. This guide reveals where data lies, what b...
SpaceX, Rocket Lab, and AST SpaceMobile retreat as a China rocket milestone and an oil price spike pressure space-sto...
CoStar Group appoints Robin Rossmann as chief financial officer, effective July 31, 2026, succeeding Christian Lown. ...
Oracle’s stock has fallen from its AI-redemption peak as management bets heavily on data-center compute. Analysts are...
Microsoft is at a crossroads as investors await the July 29 results. This article dives into why the stock could rebo...
Lucid Group sparked a sharp rally after the CEO denied bankruptcy rumors and take-private chatter. This article break...
As AI models scale, memory bandwidth becomes the bottleneck. This article digs into Nvidia's role in HBM4, the chatte...
XRP remains a top topic in 2026 as markets weigh its speed-driven use against regulatory risk and liquidity dynamics....
When Burke & Herbert shares jump, investors want to know why. This article breaks down what this burke herbert signal...
Oklo stock surged as investors weighed its plans for advanced reactors against the fast-moving AI data-center boom. T...